GENELUX Corp

GNLX Nasdaq CIK: 0001231457

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Mailing Address 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Phone 805-267-9889
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

$19.47M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 26, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
424B5 Prospectus supplement March 19, 2026 View on SEC
10-K Annual financial report March 19, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
8-K Current report of material events February 2, 2026 View on SEC

Annual Reports

10-K March 19, 2026
  • Developing new cancer treatments using the body's immune system, with lead product Olvi-Vec in Phase 3 clinical trials.
  • Proprietary CHOICE platform for developing a range of targeted virus-based cancer drugs.
View Analysis

Insider Trading

SELL 5 insiders 8 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.